KLB (JMT202 Biosimilar) Recombinant Monoclonal Antibody

1. Knockdown of beta-Klotho produced the opposite effects. In conclusion, beta-Klotho inhibits EMT and plays a tumorsuppressive role in prostate cancer (PCa) , linking FGF/FGFR/beta-Klotho signaling to the regulation of PCa progression. PMID: 29749458
2. crystal structures of free and ligand-bound beta-klotho extracellular regions that reveal the molecular mechanism that underlies the specificity of FGF21 towards beta-klotho and demonstrate how the FGFR is activated in a klotho-dependent manner PMID: 29342135
3. the metabolic FGF21/KLB/FGFR1 pathway is involved in congenital hypogonadotropic hypogonadism (CHH) Genetic screening of 334 CHH patients identified seven heterozygous loss-of-function KLB mutations in 13 patients (4%). Most patients with KLB mutations (9/13) exhibited metabolic defects. PMID: 28754744
4. We conducted a genome-wide association meta-analysis and replication study among >105,000 individuals of European ancestry and identified beta-Klotho (KLB) as a locus associated with alcohol consumption (rs11940694; P = 9.2 x 10(-12)). PMID: 27911795
5. A high expression level of KLbeta, but not KLalpha, was an independent predictive factor of short progression free survival for non-muscle invasive bladder cancer PMID: 27573985
6. Our results suggest that KLbeta plays important roles in tumor invasion and progression, and its concentration may be a valuable urinebased marker for the detection of bladder cancer. PMID: 27573985
7. obesity appears as the predominant determinant of the abnormalities in FGF21 and FGF19 levels. Opposite changes in beta-Klotho expression in fat and liver indicate potential tissue-specific alterations in the responsiveness to endocrine FGFs in obesity PMID: 24813368
8. ATF4 signaling pathway is essential for mediating the effect of ER stress on beta-klotho expression. PMID: 25727012
9. Variants in genes involved in feedback regulation of bile acid synthesis (KLB, P=0.06 and FGFR4, P=0.09) were potentially associated with the irritable bowel syndrome-diarrhea subgroup with elevated serum C4. PMID: 25070056
10. In-depth DNA sequencing identified additional genetic coding and noncoding variants in KLB that are associated with fecal bile acids excretion or colonic transit in Irritable bowel syndrome-diarrhea. PMID: 24200957
11. betaKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3beta/cyclin D1 signaling pathway. PMID: 23383245
12. KLB and FGFR1 form a 1:1 heterocomplex independent of the galectin lattice that transitions to a 1:2 complex upon the addition of FGF21. PMID: 22523080
13. KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling. PMID: 22439738
14. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PMID: 22442730
15. Deletion of the D1 and the D1-D2 linker (the D1/linker region) from FGFR1c led to beta-Klotho-independent receptor activation by FGF21, suggesting that there may be a direct interaction between FGF21 and the D1/linker region-deficient FGFR1c. PMID: 22248288
16. Polymorphism KLB rs4975017 may influence the colonic transit response to colesevelam in female patients with irritable bowel syndrome with diarrhea. PMID: 22271411
17. Data suggest that KLB is an important regulator in the immortalization of HCECs by facilitating FGF19 growth factor signaling. PMID: 22020932
18. Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho. PMID: 21653700
19. A functional KLB gene variant mediating protein stability associates with colonic transit in irritable bowel syndrome with diarrhea. This association is modulated by 2 genetic variants in FGFR4. PMID: 21396369
20. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. PMID: 20657013
21. The down-regulation of the renal klotho gene could increase renal damage induced by angiotensin II, while klotho gene induction could have therapeutic possibilities in treating angiotensin II-induced kidney damage. PMID: 16358222
22. Liver-specific activities of FGF19 require Klotho beta. PMID: 17627937
23. a functional FGF19 receptor may consist of FGF receptor (FGFR) and heparan sulfate complexed with either alphaKlotho or betaKlotho PMID: 17711860
24. High expression of Klotho is associated with ovarian disease progression PMID: 18259951
25. Both FGF23 and FGF21 require intact alpha or betaKlotho for signaling, respectively, whereas FGF19 can signal through a Klotho chimera consisting of the N terminus of alphaKlotho and the C terminus of betaKlotho. PMID: 18829467
26. These data demonstrate that the C-terminus of FGF21 is critical for binding to beta-Klotho and the N-terminus is critical for fibroblast growth factor receptor (FGFR) activation. PMID: 19059246

Show More

Hide All

HGNC: 15527

OMIM: 611135

KEGG: hsa:152831

STRING: 9606.ENSP00000257408

UniGene: Hs.90756